Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatolog…

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Yahoo

Protagonist Pictures Promotes Alice Vail to Head of Acquisitions and Development (EXCLUSIVE)

Add Yahoo as a preferred source to see more of our stories on Google. Protagonist Pictures has upped Alice Vail to head of acquisitions and development alongside a series of key internal promotions ...
Springfield News-Leader

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...
Detroit Free Press

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the ...

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...